• Read more about Meet 6 of the 20 Organizations Making an Impact Through the Global Health Innovation Grants Program

Since 2016, The Pfizer Foundation’s* Global Health Innovation Grants (GHIG) program has supported community-based initiatives that aim to improve quality of care and strengthen health systems in lower income countries. Now in its seventh year, 20 new recipients of the one-year grant program have each received US $100,000 to drive innovative solutions that help address vaccine-preventable illness in their communities.

• Read more about Pfizer’s Rocky Mount Facility Restarts Production Amid First Phase of Post-Tornado Recovery Efforts

NEW YORK, September 25, 2023 – Pfizer Inc. (NYSE: PFE) has restarted the majority of its manufacturing lines at the Rocky Mount, North Carolina facility following severe damage from a tornado that hit the site on July 19. The resumption of production also includes the launch of one line in the site’s new sterile injectable manufacturing area referred to as R3, a state-of the-art module approved earlier this year by the U.S. Food and Drug Administration (FDA). This expedited restart is a proud achievement for the Rocky Mount team; however, it is only the first step toward full recovery for the plant, as Pfizer restarts production through a phased approach, with full production across the site’s three manufacturing suites anticipated by the end of 2023. 

• Read more about Patient-Friendly Health Literacy Resources for Cancer Patients and Caregivers

Being diagnosed with cancer can be overwhelming for anyone due to the emotional impact, level of uncertainty, and potential lifestyle changes. The challenges of accessing and understanding medical information introduce additional layers of complexity when patients navigate their care.

• Read more about This Season’s COVID-19 Vaccine Rolls Outs Across U.S.

Our 2023-2024 COVID-19 vaccines are now available in pharmacies, hospitals, and clinics across the U.S., following a recommendation by The Centers for Disease Control and Prevention (CDC).

• Read more about Advancing Metabolic Research in NASH, Obesity, and Cachexia Through Pfizer’s ASPIRE Program

Did you know that certain metabolic diseases are connected to one another by underlying biological factors? Non-alcoholic steatohepatitis (NASH), obesity, and cachexia are directly linked with heart health, and together they constitute a global public health concern that risks reaching epidemic proportions.

• Read more about August Social Media Round-Up—Financial Update, World Humanitarian Day, RSV Vaccine

August typically brings two things: the dog days of summer and a lot of vacations! Social media tends to be a little quieter than usual, but that doesn’t mean there wasn’t plenty of activity on the Pfizer side of things. Our CEO provided a financial update, we celebrated World Humanitarian Day, and approvals for a pair of important vaccines.

• Read more about Race Against Resistance: Pfizer takes on AMR

A new film produced for Pfizer by BBC StoryWorks Commercial Productions puts the spotlight on the threat of antimicrobial resistance (AMR), a health crisis with global, and personal, impact. "Race Against Resistance” explores how the rise of antibiotic resistance, the process by which bacteria adapt and mutate to avoid the very drugs designed to kill them, is threatening to undo almost 100 years of progress in medicine. 

• Read more about Behind the Migraine: Pfizer Colleagues Share Their Stories

We’ve all heard it before: “Migraine is more than just a headache.” But is it really understood? Some talk about the burden of migraine—the blur of pain, vice-like pressure, nausea, insomnia, and even vertigo—but most don’t.